Interestingly, Roper et al. (2014) have shown PI3K/MEK inhibition combined with NVP-BKM120 and PD-0325901 treatment can induce tumor progression in a wild-type PIK3CA mouse model, KRAS mutant CRC, based on the inhibition of mTORC1 and MCL-1 and the activation of BIM. Here, BCL2L11 is linked to colorectal carcinoma.